Isbogrel | CAS#89667-40-3 | TXA2 synthase inhibitor

MedKoo Cat#: 561616 | Name: Isbogrel

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Isbogrel is a selective thromboxane A2 (TXA2) synthase inhibitor.

Chemical Structure

Isbogrel

CAS#89667-40-3

Theoretical Analysis

MedKoo Cat#: 561616

Name: Isbogrel

CAS#: 89667-40-3

Chemical Formula: C18H19NO2

Exact Mass: 281.1416

Molecular Weight: 281.35

Elemental Analysis: C, 76.84; H, 6.81; N, 4.98; O, 11.37

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Isbogrel; CV-4151; CV 4151; CV4151;

IUPAC/Chemical Name

(E)-7-Phenyl-7-pyridin-3-ylhept-6-enoic acid

InChi Key

UWPBQLKEHGGKKD-GZTJUZNOSA-N

InChi Code

InChI=1S/C18H19NO2/c20-18(21)12-6-2-5-11-17(15-8-3-1-4-9-15)16-10-7-13-19-14-16/h1,3-4,7-11,13-14H,2,5-6,12H2,(H,20,21)/b17-11+

SMILES Code

O=C(O)CCCC/C=C(C1=CC=CC=C1)/C2=CC=CN=C2

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 281.35 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Miyatake T, Kubota S, Miyazaki K, Watanabe S, Mafune N, Murashita T, Yasuda K. Analysis of cardiac function during hyperacute rejection: effects of PAF antagonist, TXA(2) inhibitor/antagonists, and nitroglycerin. Transplant Proc. 2000 Aug;32(5):999-1000. PubMed PMID: 10936319. 2: Umetani K, Tamura K, Komori S, Watanabe A, Ishihara T, Mochizuki S, Li B, Ijiri H. Inhibitory effect of CV4151, a thromboxane A2 synthetase inhibitor, on ventricular arrhythmias induced by coronary artery occlusion in rats. Jpn Circ J. 1996 Jun;60(6):349-54. PubMed PMID: 8844301. 3: Terashita Z, Imura Y, Nishikawa K. Inhibition of arachidonic acid induced-aggregation of rabbit platelets with CV-4151 (isbogrel), a selective thromboxane A2 (TXA2) synthase inhibitor: modulation of the antiplatelet action and prostanoid metabolism by rat aortic rings. J Lipid Mediat Cell Signal. 1996 Jan;13(1):1-8. PubMed PMID: 8821806. 4: Hsu LY, Lee CF, Chou TC, Ding YA. 2-Heteroaryl 2-substituted phenylketone derivatives and their inhibitory activity on platelet aggregation. J Pharm Pharmacol. 1995 Sep;47(9):762-7. PubMed PMID: 8583390. 5: Imura Y, Kiyota Y, Nagai Y, Nishikawa K, Terashita Z. Beneficial effect of CV-4151 (Isbogrel), a thromboxane A2 synthase inhibitor, in a rat middle cerebral artery thrombosis model. Thromb Res. 1995 Jul 1;79(1):95-107. Erratum in: Thromb Res 1996 Jul 1;83(1):111-2. Thromb Res 1996 Oct 15;84(2):143. PubMed PMID: 7495108. 6: Ackerley N, Brewster AG, Brown GR, Clarke DS, Foubister AJ, Griffin SJ, Hudson JA, Smithers MJ, Whittamore PR. A novel approach to dual-acting thromboxane receptor antagonist/synthase inhibitors based on the link of 1,3-dioxane-thromboxane receptor antagonists and -thromboxane synthase inhibitors. J Med Chem. 1995 May 12;38(10):1608-28. PubMed PMID: 7752186. 7: Terashita Z, Imura Y, Kawamura M, Kato K, Nishikawa K. Effects of thromboxane A2 synthase inhibitors (CV-4151 and ozagrel), aspirin, and ticlopidine on the thrombosis caused by endothelial cell injury. Thromb Res. 1995 Mar 1;77(5):411-21. Erratum in: Thromb Res 1996 Oct 15;84(2):144. Thromb Res 1996 Jul 1;83(1):113-5. PubMed PMID: 7778056. 8: Yamaguchi M, Maruyama N, Koga T, Kamei K, Akima M, Kuroki T, Hamana M, Ohi N. Novel antiasthmatic agents with dual activities of thromboxane A2 synthetase inhibition and bronchodilation. VI. Indazole derivatives. Chem Pharm Bull (Tokyo). 1995 Feb;43(2):332-4. PubMed PMID: 7728936. 9: Matsumoto T, Ashida Y, Tsukuda R. Pharmacological modulation of immediate and late airway response and leukocyte infiltration in the guinea pig. J Pharmacol Exp Ther. 1994 Jun;269(3):1236-44. PubMed PMID: 8014867. 10: Sasaki Y, Ishiguro N, Miura T. Effects of thromboxane A2 synthetase inhibitor (CV-4151) on reperfused skeletal muscle in rats. Eur Surg Res. 1994;26(2):101-7. PubMed PMID: 8005166. 11: Kito G, Tanabe M, Terashita Z. [Effect of CV-4151 on the cerebral hypoperfusion and production of thromboxane A2 following complete cerebral ischemia-reperfusion in dogs]. Nihon Yakurigaku Zasshi. 1993 Dec;102(6):413-20. Japanese. PubMed PMID: 8282273. 12: Häyry P, Mennander A, Paavonen T, Räisänen A, Ustinov J. Role of thromboxane in the generation of allograft arteriosclerosis in chronic rejection. Transplant Proc. 1993 Feb;25(1 Pt 1):603-4. PubMed PMID: 8438433. 13: Kawakage M, Shirakura S, Karasawa A, Takeda M, Miki I, Ishii A, Kubo K. Beneficial effect of the novel thromboxane A2 receptor antagonist sodium (E)-11-[2-(5,6-dimethyl-1-benzimidazolyl)ethylidene]-6,11- dihydrodibenz[b,e]oxepine-2-carboxylate monohydrate on collagen-induced coronary ischemia in guinea-pigs. Arzneimittelforschung. 1991 Dec;41(12):1246-50. PubMed PMID: 1815524. 14: Yasuda K, Matsui Y, Goda T, Sakuma M, Go K. [Chronic arterial occlusive diseases--drug therapy and thromboxane A2 synthetase inhibitor]. Nihon Rinsho. 1991 Sep;49(9):2149-54. Japanese. PubMed PMID: 1960880. 15: Asai F, Ito T, Ushiyama S, Matsuda K, Oshima T. In vitro antiplatelet profiles of the new thromboxane synthetase inhibitor sodium 2-(1-imidazolylmethyl)-4,5-dihydrobenzo[b]thiophene-6-carboxylate. Arzneimittelforschung. 1991 May;41(5):506-10. PubMed PMID: 1898421. 16: Hattori R, Kodama K, Takatsu F, Yui Y, Kawai C. Randomized trial of a selective inhibitor of thromboxane A2 synthetase, (E)-7-phenyl-7-(3-pyridyl)-6-heptenoic acid (CV-4151), for prevention of restenosis after coronary angioplasty. Jpn Circ J. 1991 Apr;55(4):324-9. PubMed PMID: 2046138. 17: Watts IS, Wharton KA, White BP, Lumley P. Thromboxane (Tx) A2 receptor blockade and TxA2 synthase inhibition alone and in combination: comparison of anti-aggregatory efficacy in human platelets. Br J Pharmacol. 1991 Feb;102(2):497-505. PubMed PMID: 1826620; PubMed Central PMCID: PMC1918008. 18: Kuroe K, Kurokawa T, Nishikimi M, Nonami T, Harada A, Nakao A, Takagi H. Effects of thromboxane A2 synthetase inhibitor on postischemic liver injury in rats. Eur Surg Res. 1991;23(1):20-6. PubMed PMID: 1879452. 19: Imura Y, Terashita Z, Nishikawa K. The role of thromboxane (TX) A2 in rabbit arterial thrombosis induced by endothelial damage. Thromb Res. 1990 Jul 1;59(1):195-205. PubMed PMID: 2119075. 20: Watts IS, White BP, Wharton KA, Lumley P. Comparison of GR32191, R68070 and CV-4151 upon U-46619- and collagen-induced platelet aggregation in vitro and ex vivo. Br J Pharmacol. 1989 Dec;98 Suppl:842P. PubMed PMID: 2611538.